Antihypertensive efficacy and tolerability of candesartan–hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy

MLA

Bönner, Gerd, et al. “Antihypertensive Efficacy and Tolerability of Candesartan–hydrochlorothiazide 32/12.5 Mg and 32/25 Mg in Patients Not Optimally Controlled with Candesartan Monotherapy.” Blood Pressure, vol. 17, Jan. 2008, pp. 22–30. EBSCOhost, https://doi.org/10.1080/08038020802519220.

APA

Bönner, G., Balparda, C., Cuneo, C., Rojas, C., Jure, H., Luquez, H., Montaña, O., Salomone, O., Rodenas, P., Aizenberg, D., Lecocq, L., Saint-Lannes, M., Guerin, P., Jourde, P., Frohn, M., Richter, D., Leyendecker, P., Cantin, T., Smila, D., … Vinyoles, E. (2008). Antihypertensive efficacy and tolerability of candesartan–hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy. Blood Pressure, 17, 22–30. https://doi.org/10.1080/08038020802519220

Chicago

Bönner, Gerd, C. Balparda, C. Cuneo, C. Rojas, H. Jure, H. Luquez, O. Montaña, et al. 2008. “Antihypertensive Efficacy and Tolerability of Candesartan–hydrochlorothiazide 32/12.5 Mg and 32/25 Mg in Patients Not Optimally Controlled with Candesartan Monotherapy.” Blood Pressure 17 (January): 22–30. doi:10.1080/08038020802519220.